Sanofi Reassures Investors About Diabetes Franchise, Says Late-Stage Pipeline Will Reduce Lantus Dependence
Executive Summary
Sanofi used a keenly awaited investor day to extoll its late-stage pipeline and voice optimism about its key diabetes franchise, but avoided mention of the “elephant in the room” – the pharma’s lack of a CEO after last month’s dramatic expulsion of Chris Viehbacher.
You may also be interested in...
Biogen Lures Viehbacher Back From Venture Capital As CEO
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.